Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
The CADTH Common Drug Review (CDR) approach to reviewing Inflectra followed the CDR Procedure and Submission Guidelines for Subsequent Entry Biologics (March, 2014). The CDR team reviewed the information provided by the manufacturer regarding product information, indications under review, the manufacturer’s requested listing criteria, biosimilarity, extrapolation, and cost. Clinical Study Reports and published articles were also appraised. Reviewers provided a critical appraisal of the clinical evidence, a discussion of extrapolation from the indications of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) to inflammatory bowel disease (IBD), and an evaluation of cost.
Drug | Inflectra (infliximab) |
---|---|
Indication |
|
Listing request | For each indication, list in a similar manner to the public plan listing criteria for Remicade |
Dosage form(s) | Intravenous infusion (powder for solution, 100 mg/vial) |
NOC date | June 10, 2016 |
Manufacturer | Hospira, a Pfizer Company |
Contents
- Abbreviations
- Executive Summary
- 1. Product Information
- 2. Indications
- 3. Manufacturer’s Requested Listing Criteria
- 4. Biosimilarity
- 5. Critical Appraisal of Clinical Studies
- 6. Extrapolation of Indications
- 7. Cost Comparison
- 8. Discussion
- 9. Conclusion
- APPENDIX 1. Additional Data
- APPENDIX 2. Drug Plan Listing Status for Reference Product
- APPENDIX 3. Summary of Patient Input
- References
This review report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH).
Through the CADTH Common Drug Review (CDR) process, CADTH undertakes reviews of drug submissions, resubmissions, and requests for advice, and provides formulary listing recommendations to all Canadian publicly funded federal, provincial, and territorial drug plans, with the exception of Quebec.
The report contains an evidence-based clinical and/or pharmacoeconomic drug review, based on published and unpublished material, including manufacturer submissions; studies identified through independent, systematic literature searches; and patient-group submissions. In accordance with CDR Update — Issue 87, manufacturers may request that confidential information be redacted from the CDR Clinical and Pharmacoeconomic Review Reports.
The information in this report is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment with respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this document to ensure that its contents are accurate, complete, and up-to-date as of the date of publication, CADTH does not make any guarantee to that effect. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document or in any of the source documentation.
This document is intended for use in the context of the Canadian health care system. Other health care systems are different; the issues and information related to the subject matter of this document may be different in other jurisdictions and, if used outside of Canada, it is at the user’s risk. This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.
CADTH takes sole responsibility for the final form and content of this document, subject to the limitations noted above. The statements and conclusions in this document are those of CADTH and not of its advisory committees and reviewers. The statements, conclusions, and views expressed herein do not necessarily represent the views of Health Canada or any Canadian provincial or territorial government. Production of this document is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Ontario, Prince Edward Island, Saskatchewan, and Yukon.
You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.
Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.
- NLM CatalogRelated NLM Catalog Entries
- Review Biosimilars in inflammatory bowel disease: ready for prime time?[Curr Opin Gastroenterol. 2015]Review Biosimilars in inflammatory bowel disease: ready for prime time?Gomollón F. Curr Opin Gastroenterol. 2015 Jul; 31(4):290-5.
- Review Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: An Updated Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines[ 2017]Review Switching from Innovator to Biosimilar (Subsequent Entry) Infliximab: An Updated Review of the Clinical Effectiveness, Cost-Effectiveness, and Guidelines. 2017 Jan 18
- Review Golimumab for the treatment of psoriatic arthritis.[Health Technol Assess. 2011]Review Golimumab for the treatment of psoriatic arthritis.Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N. Health Technol Assess. 2011 May; 15 Suppl 1:87-95.
- Review Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.[Clin Gastroenterol Hepatol. 2016]Review Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL. Clin Gastroenterol Hepatol. 2016 Dec; 14(12):1685-1696. Epub 2016 May 21.
- Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: A nationwide population-based study.[Mod Rheumatol. 2017]Association of inflammatory bowel disease with ankylosing spondylitis and rheumatoid arthritis: A nationwide population-based study.Bae JM, Choo JY, Kim KJ, Park KS. Mod Rheumatol. 2017 May; 27(3):435-440. Epub 2016 Jul 26.
- Subsequent Entry Biologic Review Report: Inflectra (infliximab)Subsequent Entry Biologic Review Report: Inflectra (infliximab)
Your browsing activity is empty.
Activity recording is turned off.
See more...